Due to health issues, this site is no longer maintained and will be shut down shortly. |
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
Note: This is not a U.S. company, but they cross-list their shares on a U.S. stock exchange - see the related symbol QF:NMED.
$2.91 +0.04 (1.22%)
As of 03/24/2023 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.